Skip to content

Study · Observational study · n = 131 · 2024

4 results

One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.

Kim MJ, Kim HS, Cho YK, Jung CH, Lee WJ

Clinical therapeutics27 Jul 2024Cited by 3 (Europe PMC)

PMID39069432 (opens in a new tab)DOI10.1016/j.clinthera.2024.06.024 (opens in a new tab)PepBankPUB-39069432
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with diabetic kidney disease, dulaglutide use was linked to lower HbA1c than baseline.

    In plain wordsIn patients with diabetic kidney disease, dulaglutide use was linked to lower long-term blood sugar than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n = 131

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1.2%
    12-month change
    Standard error
    0.1%
    HbA1c change

    Source sentences

    Summary
    Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: -1.2 ± 0.1%, -34.8 ± 6.9 mg/dL, and -2.3 ± 0.5 kg, respectively; P < 0.001).
    2 context sentences
    Summary · context
    This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023.
    Summary · context
    The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals.
  2. 02HumanObservational studyEfficacy outcome

    In patients with diabetic kidney disease, dulaglutide use was linked to lower fasting plasma glucose than baseline.

    In plain wordsIn patients with diabetic kidney disease, dulaglutide use was linked to lower fasting blood sugar than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 131

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    FPG change
    −34.8 mg/dL
    12-month change
    Standard error
    6.9 mg/dL
    FPG change

    Source sentences

    Summary
    Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: -1.2 ± 0.1%, -34.8 ± 6.9 mg/dL, and -2.3 ± 0.5 kg, respectively; P < 0.001).
    2 context sentences
    Summary · context
    This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023.
    Summary · context
    The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals.
  3. 03HumanObservational studyEfficacy outcome

    In patients with diabetic kidney disease, dulaglutide use was linked to lower body weight than baseline.

    In plain wordsIn patients with diabetic kidney disease, dulaglutide use was linked to lower weight than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight change
    Study

    n = 131

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −2.3 kg
    12-month change
    Standard error
    0.5 kg
    weight change

    Source sentences

    Summary
    Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: -1.2 ± 0.1%, -34.8 ± 6.9 mg/dL, and -2.3 ± 0.5 kg, respectively; P < 0.001).
    2 context sentences
    Summary · context
    This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023.
    Summary · context
    The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In dulaglutide-treated patients with diabetic kidney disease, HbA1c reduction differed significantly by baseline HbA1c.

    In plain wordsIn patients with diabetic kidney disease using dulaglutide, blood sugar reductions differed between groups defined by initial HbA1c.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedHbA1c reduction by baseline HbA1c
    Study

    n: not reported in source

    Comparator
    Baseline HbA1c subgroups
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Subgroup analysis revealed significant differences in HbA1c reduction based on baseline HbA1c.
    2 context sentences
    Summary · context
    This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023.
    Summary · context
    The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.